Did Bioventus beat or miss consensus estimates last quarter?

What is Bioventus's latest dividend and current dividend yield?

What is the market's earnings forecast for Bioventus next quarter?

What is the revenue and EPS growth rate for Bioventus year over year?

What guidance did Bioventus's management provide for the next earnings period?

What were the key takeaways from Bioventus's earnings call?

What is Bioventus's gross profit margin?

What does Bioventus do and what are its main business segments?

- **Q3 Execution**: 8% organic growth, 19% EBITDA margin, $30M cash flow, validating 2025 guidance.
- **New Product Momentum**: PNS/PRP set to accelerate 2026+ growth.
- **Balance Sheet Strength**: <3x leverage, $42M cash, $300M+ debt reduction.
- **Risk Management**: Tariffs/FX hedged by operational excellence.
- **2025-2026 Transition**: 2025 execution risk/reward balanced.


**【CEO Summary Section】**
- Q3 2025 revenue of $139 million, up 8% organically, driven by above-market growth across all segments.
- Pain treatments revenue accelerated 6% QoQ, led by DUROLANE's strong volume growth and new account wins.
- Surgical solutions grew 9%, with bone graft substitutes (BGS) and ultrasonics leading the charge.
- Restorative therapies (Exogen) achieved double-digit organic growth despite the advanced rehabilitation divestiture.
- New product launches in PNS (StimTrial/TalisMann) and PRP (Excel) are expected to contribute 200+ basis points to 2026 growth.
- Adjusted EBITDA margin expanded 220 bps to 19%, with cash flow from operations tripling QoQ to $30 million.
- 2025 guidance reaffirmed: 6-8% organic revenue growth, $112-116M adjusted EBITDA, $0.64-0.68 EPS.

**【CFO Financial Commentary】**
- Q3 GAAP net income of $13M, up 200% YoY, driven by gross margin expansion and expense savings from divestiture.
- International segment on track for double-digit organic growth, offsetting $5M tariffs/FX headwinds.
- Cash conversion ratio >100%, with year-to-date cash from ops up 88%.

**【Q&A Highlights】**
- DUROLANE outpaced legacy HA therapies, with GELSYN facing price pressure but still contributing to overall portfolio strength.
- BGS distributor ramp-up driving Q4 surgical acceleration, with ultrasonics' clinical differentiation key to penetrating spine market.
- PNS commercial scale-up expected to accelerate 2026 growth, balancing investments with margin expansion.
- 2026 guidance pending, but 2025 execution validates long-term $1B+ vision.

**Key Takeaways**
- **Revenue Growth**: 8% organic Q3 beat with new products (PNS/PRP) set to drive 2026+ expansion.
- **Profitability**: 19% EBITDA margin, $30M+ cash flow, net leverage <3x, debt < $300M by year-end.
- **Risks**: Tariffs/FX ($5M annualized), but strong execution offsetting headwinds.
- **2025 Guidance Reaffirmation**: On track for 6-8% growth, 100+ bps margin expansion.

**2026 Outlook**: PNS/PRP to add 200+ bps growth, positioning for $1B+ with >20%+ margins.


Bioventus Inc. (BVS) Q3 2025 Earnings Call Transcript

- **Q2 Growth**: $148M revenue, 6% organic growth driven by Surgical (+11%) and Exogen (+double-digit). 
- **PNS Launch**: $100M+ potential from StimTrial/TalisMann in fast-growing PNS market. 
- **Cash Flow**: $26M Q2, FY25 target nearly double FY24. 
- **Margins**: 23% EBITDA margin, 100bps expansion target. 
- **Tariffs Impact**: $3M FY25, offset by strong cost control. 
- **Debt Refinancing**: $2M annual savings, extended maturity. 
- **Exogen Recovery**: Targeting $100M+ revenue with mid-single-digit growth.

**【CEO Summary Section】**
- Q2 revenue of $148 million, in line with expectations, with 6% organic growth driven by Surgical Solutions (11% growth) and Restorative Therapies (double-digit growth in Exogen). 
- Adjusted EBITDA of $34 million, up 3% YoY, with margin expansion to 23%. 
- Launched PNS products (StimTrial and TalisMann) targeting $500M+ U.S. market, expected to contribute $100M+ in revenue. 
- Reaffirmed 2025 guidance: 6-8% organic revenue growth, $112-116M adjusted EBITDA, $0.64-0.68 EPS. 
- FY25 cash flow to nearly double YoY, with net leverage <2.5x by year-end. 

**【CFO Financial Commentary】**
- Surgical Solutions: $52M revenue (+11%), driven by ultrasonics and BGS (12% growth). 
- Pain Treatments: $58M (+1%), with HA growth offset by tough comps; DUROLANE volume up mid-single digits. 
- Restorative Therapies: $38M (-32% due to divestiture), Exogen up 11%. 
- Intl: $10M (+12%), organic +24%. 
- Gross margin 76% (up 50bps), OpEx down $4M YoY. 
- Cash flow $26M Q2, +$11M YoY, with $30M revolver draw for debt reduction. 
- Tariffs impact $3M FY25, FX impact $2M absorbed YTD. 

**【Q&A Highlights】**
- **Pain Treatments**: 4-5% organic growth Q2, 6-8% FY25; DUROLANE volume up mid-single digits, IDN wins to accelerate. 
- **BGS**: Q2 growth 10%, accelerating in H2 with new distributors. 
- **Exogen**: Double-digit Q2 growth, targeting $100M+ revenue. 
- **R&D**: Moderate spend, but material % of revenue for PNS/ultrasonics. 
- **Tariffs**: $3M FY25 impact, mostly in H2; FX stable. 
- **PNS Launch**: Limited Q3 rollout, broader 2026; 200bps+ growth contribution potential. 
- **Debt**: 5% annual amortization, $2M interest savings. 
- **Margins**: 100bps EBITDA margin expansion target. 
- **Cash Flow**: $60M+ FY25, up from $32M FY24.

Bioventus (BVS)-6 Aug 25-2025 Q2 Earnings call transcript

- **Q1 Growth Momentum**: $124M revenue (+5% organic), 33% EPS increase to $0.08, driven by Ultrasonics (+50% capital sales) and Exogen expansion.
- **Strategic Priorities**: (1) 6-8% 2025 revenue growth via pain treatment account wins; (2) 100+bps EBITDA margin expansion; (3) Cash flow nearly doubling to $100M+.
- **PRP Partnership**: APEX Biologix XCELL system adds $0+ 2025 revenue, targeting $100M+ PRP market.
- **Tariff Resilience**: Minimal impact ( <$1M/year), 90%+ products U.S.-sourced or exempt.

**【CEO Summary Section】**
- Q1 2025 revenue of $124 million reflected 5% organic growth, driven by double-digit growth in Surgical Solutions (Ultrasonics) and Restorative Therapies (Exogen). Adjusted EPS of $0.08 increased 33% year-over-year.
- Key priorities: (1) Above-market revenue growth through Surgical Solutions expansion and pain treatment account wins; (2) 100+ basis points EBITDA margin expansion via gross margin optimization; (3) Doubling cash flow through reduced interest expenses and operational efficiency.
- Launched PRP partnership with APEX Biologix, targeting synergies with HA treatments and orthopedic surgeons.
- Tariffs currently minimal impact, with 90%+ products sourced in the U.S. or under exemptions.

**【CFO Financial Commentary】**
- Adjusted EBITDA of $19 million (-16% YoY) due to divestiture and $1.1 million FX loss. Gross margin 75% (-70bps YoY) from channel mix and freight costs.
- Operating expenses down $3 million YoY, driven by divestiture savings. Q1 cash outflow ($19M) due to annual bonuses; expect Q2+ cash flow acceleration.
- Full-year guidance reaffirmed: 6-8% organic revenue growth, $112-116M EBITDA, $0.64-0.68 EPS. Net leverage to drop below 2.5x by year-end.

**【Q&A Key Highlights】**
- **Pain Treatment Market**: DUROLANE growth driven by single-injection shift, 10% CMS ASP increase. Q2 2025 growth acceleration expected post-2024 competitor supply issues.
- **Tariff Strategy**: Monitoring but no material impact; 90%+ products U.S.-sourced. Focus on growth execution over external factors.
- **International Expansion**: New OUS leader prioritizing high-potential countries and product launches, targeting disciplined growth.
- **Leverage & M&A**: Targeting <2.0x leverage; open to M&A only for synergistic opportunities (e.g., PRP partnership).

Bioventus (BVS)-6 May 25-2025 Q1 Earnings call transcript

- **Revenue Powerhouse**: 14% organic growth in Q4, 12% total for 2024, driven by Surgical Solutions (+18%) and Pain Treatments (+17%).
- **Profit Machine**: 23% EBITDA growth to $109M, 160bps margin expansion, debt down $50M to 3.0x leverage.
- **2025 Outlook**: $560-570M revenue (+6-8%), 100bps margin expansion, FCF nearly doubles.
- **Growth Engines**: Ultrasonics (+20%+), Exogen (7%+), and DUROLANE (2x market growth) set to accelerate.

**【CEO 2024 Yearly Performance Summary】**
- **Revenue Growth**: 12% total growth (14% organic), driven by Surgical Solutions (18%), Pain Treatments (17%), and Restorative Therapies (7%).
- **Profitability**: Adjusted EBITDA of $109M (+23%), margin expanded 160bps to 19.5%. Debt reduced by $50M, net leverage to 3.0x.
- **Strategic Wins**: Divested Advanced Rehabilitation ($45.4M revenue), onboarding new leadership for Ultrasonics, and reversing 5-year decline in Exogen.

**【CFO 2024 Q4 Financials】**
- **Top Line**: $154M revenue (+14% YoY), Surgical Solutions up 18% (Ultrasonics +20%+), Pain Treatments +17%.
- **Bottom Line**: Adjusted EBITDA $28M (+28%), Adj. EPS $0.15 (+100%). Operating cash flow $19M, FCF to nearly double in 2025.
- **Segment Breakdown**: 
  - **Surgical**: Ultrasonics +20%+, BGS returning to double-digit growth post-supply chain fixes.
  - **Pain**: DUROLANE outperforms market, HA +17%Q4 but expects Q1 headwind from distributor destocking.
  - **Restorative**: Exogen +7% YoY, targeting low-mid single digits in 2025.

**【2025 Financial Guidance】**
- **Revenue**: $560-570M (+6-8% organic), Surgical Solutions to drive double-digit growth.
- **EBITDA**: $112-116M (+8-12%), targeting 100bps margin expansion.
- **Leverage**: Projected to 2.5x by year-end, enabling selective M&A.

**【Q&A Key Takeaways】**
- **Pain Treatments**: DUROLANE growth to continue via volume, not price, with 2x market growth rate.
- **Bone Graft Substitutes**: Supply resolved, targeting double-digit growth in H2 2025.
- **Exogen**: 7%+ growth achievable with improved sales execution.
- **Capital Allocation**: Debt reduction priority, but open to high ROI inorganic opportunities post-2.5x leverage.

BVS

BVS fundamentals

Earnings Call

You can ask Aime